Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DigestHB is a multi-ingredient dietary supplement developed by Enzymedica, specifically formulated to address occasional heartburn and indigestion. The product utilizes a synergistic approach by combining acid-neutralizing minerals with mucosal-protective agents and digestive enzymes. It contains calcium carbonate and magnesium carbonate, which provide immediate relief by neutralizing excess gastric acid. Additionally, it features Zinc L-Carnosine (PepZin GI), a chelated compound known for its ability to support and protect the gastric mucosal lining. To address the root causes of indigestion, DigestHB includes a proprietary blend of enzymes, such as amylase, lipase, and cellulase, which facilitate the efficient breakdown of carbohydrates, fats, and fibers, thereby reducing the likelihood of reflux and digestive discomfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DigestHB.